Translating Nanotechnologies into Clinical Settings to Measure Response to Novel Cancer Agents: Nano Seminar Series
Seminar | December 1 | 2-3 p.m. | 180 Tan Hall | Note change in location
Prof. Alice C. Fan, MD, Stanford University School of Medicine, Oncology
My laboratory studies how kinase inhibitors modulate protein signaling in patients with cancer. A barrier to this work has been the requirement for serial tumor samples from patients in order to measure changes in protein activation. To overcome this barrier, I use nanotechnologies to profile proteins in small numbers of patient tumor cells.
Our work addresses a series of questions at different levels. First, how can we robustly measure changes in proteins, the direct targets of kinase inhibitors, in our patients? I will discuss how we developed a novel nanoimmunoassay that can be used to profile changes in even single phosphorylations, in patient cells during therapy targeting kinase pathways. Second, do proteins measured in a single fine needle aspirate biopsy represent the whole tumor? We have begun to use nanoimmunoassays to characterize regional tumor heterogeneity in primary tumors. Third, can a less invasive approach to obtain tumor cells be developed?
I will discuss using nanotechnologies to isolate and analyze circulating tumor cells in a prospective clinical trial. At the end of the seminar, the audience will have knowledge of how nanotechnologies are being integrated into translational and clinical studies of targeted therapies for cancer.